¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 32¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 14.3%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Á¦Ç° ¾ÈÀü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ¿¡ µû¶ó ¹Ì»ý¹°ÇÐÀû ¾ÈÀü¼º °Ë»ç µµ±¸¸¦ ÃËÁøÇϱâ À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ Â÷¿øÀÇ ³ë·ÂÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.
¹Ì»ý¹°ÇÐÀû ¾ÈÀü¼º ½ÃÇè¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇØ °¢ ±â°ü¿¡¼ ¹ßÇ¥ÇÑ ¼ö¸¹Àº °£Ç๰Àº ¹ÙÀÌ¿À¹öµç ½ÃÇèÀÇ ¹Ì·¡ ¼ºÀå Àü¸ÁÀ» ³ÐÇôÁÖ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ º¸°Ç»çȸº¹ÁöºÎ¿Í Áúº´ÅëÁ¦¼¾ÅÍ´Â ½ÇÇè½Ç »ý¹°º¸¾È ¹× À§ÇèÆò°¡, ¿À¿°Á¦°Å ¹× ¸ê±Õ, »ý¹°ÇÐÀû µ¶¼Ò ¹× ½ÇÇè½ÇÀÇ »ý¹°¾ÈÀü ¼öÁذú °ü·ÃµÈ Á¤º¸¸¦ Æ÷ÇÔÇÑ '¹Ì»ý¹° ¹× »ý¹°ÀÇÇÐ ½ÇÇè½ÇÀÇ »ý¹°¾ÈÀü(BMBL)'À» ¹ß°£Çß½À´Ï´Ù.
Á¦¾à, »ý¸í°øÇÐ, ÀÇ·á±â±â, ½Äǰ ¹× À½·á »ê¾÷ÀÇ ¼ºÀåÀÌ ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀåÀÇ ³ôÀº ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯¸í ±â¾÷µéÀÇ R&D ÅõÀÚ Áõ°¡´Â ¹Ì»ý¹° ¿À¿°À¸·Î ÀÎÇÑ ¼Õ½Ç¿¡ ´ëÀÀÇϱâ À§ÇØ ÃÖÁ¾»ç¿ëÀÚµéÀÌ °íÈ¿À²ÀÇ ¹ÙÀÌ¿À¹öµç ½ÃÇè µµ±¸¸¦ äÅÃÇϵµ·Ï À¯µµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀüÀÓ»ó½ÃÇè¿¡¼ ±âº»ÀûÀÎ ÀǾàǰ ¾ÈÀü¼º µ¥ÀÌÅÍ ¿ä±¸»çÇ׿¡ ´ëÇÑ ¿ä±¸´Â ¹ÙÀÌ¿À¹öµç ½ÃÇè µµ±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Á¦Ç°º°·Î´Â ¹èÁö, ½Ã¾à ¹× ŰƮÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ¸·Î ÀÎÇØ ¼Ò¸ðǰ ºÎ¹®ÀÌ 2023³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- PCR Àåºñ´Â ¼¼±Õ¼º ¹ÙÀÌ¿À¹öµçÀÇ ½Å¼ÓÇÑ ºÐ¼®À» ¿ëÀÌÇÏ°Ô ÇÏ¿© ³ôÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÕ´Ï´Ù.
- È£±â¼º ¼¼±Õ¼ö °Ë»ç´Â ¹èÁö¸¦ ÅëÇÑ È£±â¼º ¼¼±Õ ºÐ¸®°¡ ¿ëÀÌÇØ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- ¿ø·á °Ë»ç´Â Á¦Ç° ¸®ÄÝ Áõ°¡¿Í Á¦Ç° ǰÁú¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ ÀÌ »ê¾÷ÀÇ ³ôÀº ¼ºÀåÀ¸·Î 2023³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- CMOÀÇ ¼ö°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¾Æ¿ô¼Ò½Ì ¼ºñ½ºÀÇ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù.
- ÁÖ¿ä ±â¾÷ÀÇ ³ôÀº R&D ºñ¿ë°ú ¹Ì±¹ÀÇ ³ôÀº ÀÇ·áºñ ÁöÃâ·Î ÀÎÇØ ºÏ¹Ì°¡ 2023³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå ¼Ò°³/°èÅë Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå ºÐ¼® Åø
Á¦4Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
- ¼Ò¸ðǰ
- ±â±â
Á¦5Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : ½ÃÇè ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : ½ÃÇè º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
- È£±â¼º Ä«¿îÆ® ½ÃÇè
- Çø±â¼º ±Õ¼ö½ÃÇè
- Áø±Õ/°õÆÎÀ̼ö½ÃÇè
- Æ÷ÀÚ¼ö½ÃÇè
Á¦6Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
- ¿øÀÚÀç ½ÃÇè
- ÀÇ·á±â±â ½ÃÇè
- °øÁ¤³» Àç·á ½ÃÇè
- ¸ê±Õ °ËÁõ ½ÃÇè
- ±â±â ¼¼Á¤ °ËÁõ
Á¦7Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
- Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
- ÀÇ·á±â±â Á¦Á¶¾÷ü
- °è¾à Á¦Á¶ Á¶Á÷
- ½Äǰ ¹× À½·á¡¤³ó»ê¹° Á¦Á¶¾÷ü
- ¹Ì»ý¹° °Ë»ç ¿¬±¸¼Ò
Á¦8Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå Á¡À¯À², Áö¿ªº°, 2023³â ¹× 2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï »óȲ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷ ºÐ·ù
- ±â¾÷ È÷Æ®¸Ê ºÐ¼®
- ±â¾÷ °³¿ä
- Charles River Laboratories
- Merck KGaA
- SGS Societe Generale de Surveillance SA.
- WuXi AppTec
- BD
- North American Science Associates, LLC
- Nelson Laboratories, LLC
- Thermo Fisher Scientific Inc
- BIOMERIEUX
- Pacific Biolabs
ksm 24.11.01
Bioburden Testing Market Growth & Trends:
The global bioburden testing market size is expected to reach USD 3.22 billion by 2030, registering a CAGR of 14.3% during the forecast period, according to a new report by Grand View Research, Inc. The market is expected to showcase upward trend in the forthcoming years owing to growing concerns about product safety. This has led to various government initiatives to promote microbiological safety testing tools.
A number of publications released by organizations to promote awareness regarding microbiological safety testing is broadening the future growth prospects of bioburden testing. For instance, the U.S. Department of Health and Human Services and Centers for Disease Control published Biosafety in Microbiological and Biomedical Laboratories (BMBL), which includes information pertaining to laboratory biosecurity and risk assessment, decontamination and sterilization, and biological toxins and biosafety levels in laboratories.
Growth of pharmaceutical, biotechnology, medical device, and food and beverage industries have contributed to the high growth of the bioburden testing market. In addition, increase in R&D investments by prominent companies is expected to encourage end users to adopt highly efficient bioburden testing tools to counter possible losses due to microbial contamination. Moreover, requirement for basic drug safety data requirements for preclinical studies is expected to fuel the demand for bioburden testing tools.
Bioburden Testing Market Report Highlights:
- On the basis of product, consumables segment dominated the market in 2023 owing to a wide use of culture media and reagents and kits.
- The PCR instruments facilitate rapid analysis of bacterial bioburden, thus, fostering high market growth.
- The aerobic count-testing held largest market share in 2023 due to easy isolation of aerobic bacteria by culture media.
- Raw material testing is anticipated to showcase lucrative growth during the forecast period owing to the increasing number of product recalls and concern regarding product quality.
- On the basis of end-use, pharmaceutical and biotechnology companies dominated the market in 2023 owing to the high growth of this industry.
- The number of CMOs is increasing significantly, which has led to a rise in outsourcing services, thus, driving the segment growth.
- North America held the largest revenue share in 2023 due to high R&D spending by key companies and high healthcare spending in the U.S.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Bioburden Testing Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Billion)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Bioburden Testing Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
Chapter 4. Bioburden Testing Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Bioburden Testing Market: Product Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Consumables
- 4.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.1.1. Culture Media
- 4.3.1.1.1. Culture Media Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.1.2. Reagents and Kits
- 4.3.1.2.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.1.1. Automated Microbial Identification Systems
- 4.4.1.1.1. Automated Microbial Identification Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.1.2. PCR Instruments
- 4.4.1.2.1. PCR Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Bioburden Testing Market: Test Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Bioburden Testing Market: Test Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Aerobic Count Testing
- 5.3.1. Aerobic Count Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Anaerobic Count Testing
- 5.4.1. Anaerobic Count Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Fungi/Mold Count Testing
- 5.5.1. Fungi/Mold Count Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Spore Count Testing
- 5.6.1. Spore Count Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Bioburden Testing Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Bioburden Testing Market: Application Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. Raw Material Testing
- 6.3.1. Raw Material Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Medical Device Testing
- 6.4.1. Medical Device Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. In-Process Material Testing
- 6.5.1. In-Process Material Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Sterilization Validation Testing
- 6.6.1. Sterilization Validation Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. Equipment Cleaning Validation
- 6.7.1. Equipment Cleaning Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Bioburden Testing Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Bioburden Testing Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
- 7.3. Pharmaceutical & Biotechnology Companies
- 7.3.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Medical Device Manufacturers
- 7.4.1. Medical Device Manufacturers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Contract Manufacturing Organizations
- 7.5.1. Contract Manufacturing Organizations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Manufacturers of Food & Beverage and Agricultural Products
- 7.6.1. Manufacturers of Food & Beverage and Agricultural Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Microbial Testing Laboratories
- 7.7.1. Microbial Testing Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Bioburden Testing Market: Regional Estimates & Trend Analysis
- 8.1. Bioburden Testing Market Share, By Region, 2023 & 2030 (USD Million)
- 8.2. North America
- 8.2.1. North America Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Canada Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Mexico Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. Europe Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
- 8.3.2.1. UK Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Germany Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
- 8.3.4.1. France Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Italy Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Spain Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Denmark Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Sweden Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Norway Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. China
- 8.4.2.1. China Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Japan
- 8.4.3.1. Japan Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
- 8.4.4.1. India Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. South Korea
- 8.4.5.1. South Korea Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. Australia
- 8.4.6.1. Australia Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
- 8.4.7.1. Thailand Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Brazil Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Argentina Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Saudi Arabia
- 8.6.2.1. Saudi Arabia Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. UAE
- 8.6.3.1. UAE Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. South Africa
- 8.6.4.1. South Africa Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Kuwait Bioburden Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Heat Map Analysis
- 9.4. Company Profiles
- 9.4.1. Charles River Laboratories
- 9.4.1.1. Participant's Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Merck KGaA
- 9.4.2.1. Participant's Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. SGS Societe Generale de Surveillance SA.
- 9.4.3.1. Participant's Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. WuXi AppTec
- 9.4.4.1. Participant's Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. BD
- 9.4.5.1. Participant's Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. North American Science Associates, LLC
- 9.4.6.1. Participant's Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Nelson Laboratories, LLC
- 9.4.7.1. Participant's Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Thermo Fisher Scientific Inc
- 9.4.8.1. Participant's Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. BIOMERIEUX
- 9.4.9.1. Participant's Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. Pacific Biolabs
- 9.4.10.1. Participant's Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Recent Developments/ Strategic Initiatives